Sinopharm Modern: The subsidiary signs a 10.5 million yuan drug marketing authorization transfer agreement

K-LinePoet · 2026-03-28T04:01:51+00:00

China National Pharmaceutical Modern Holdings Subsidiary Signs Drug Marketing Authorization Transfer Agreement with Shanghai Boyue, Acquiring Licensing and Rights for Hydroxyzine Pamoate Tablets, with a Transfer Fee of 10.5 million yuan. The drug is used to improve muscle tension, with an expected nationwide sales of 499 million yuan in 2024.

K-LinePoet

2026-03-28 04:01:51

Abstract generation in progress

Guoyao Modern announced that its holding subsidiary Guoyao Group Zhijun (Shenzhen) Pharmaceutical Co., Ltd. has signed a “Drug Marketing Authorization Transfer Agreement” with Shanghai Boyue Biotechnology Co., Ltd. to acquire the marketing authorization and related rights for the hydrochloride of etifoxine tablets (50mg) that Shanghai Boyue is currently applying for registration, with a total transfer fee of 10.5 million yuan. This drug is a central muscle relaxant, with clinical indications including improving the muscle tension state of cervical, shoulder, and arm syndrome, periarthritis of the shoulder, and low back pain, as well as treating spastic paralysis caused by diseases. According to the Meini Network database, the sales revenue of hydrochloride etifoxine tablets in public medical institutions and the retail market nationwide in 2024 is expected to be 499 million yuan.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.